EU nod for Shire’s longer-acting haemophilia A therapy
Shire’s Adynovi has been approved for use in Europe for on-demand and prophylactic use in patients 12 years and older with the rare bleeding disorder haemophilia A.
Read More
Tag: Adynovi
Ten new medicines leap towards EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
